HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Adalimumab in Active and Inactive, Non-Infectious Uveitis : Global Results from the VISUAL I and VISUAL II Trials

This item is licensed under:Creative Commons Attribution-NonCommercial 3.0 Unported

Files in This Item:
Adalimumab in Active and Inactive Non Infectious Uveitis Global Results from the VISUAL I and VISUAL II Trials.pdf969.55 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Adalimumab in Active and Inactive, Non-Infectious Uveitis : Global Results from the VISUAL I and VISUAL II Trials
Authors: Goto, Hiroshi Browse this author →KAKEN DB
Zako, Masahiro Browse this author →KAKEN DB
Namba, Kenichi Browse this author →KAKEN DB
Hashida, Noriyasu Browse this author →KAKEN DB
Kaburaki, Toshikatsu Browse this author →KAKEN DB
Miyazaki, Masanori Browse this author →KAKEN DB
Sonoda, Koh-Hei Browse this author →KAKEN DB
Abe, Toshiaki Browse this author →KAKEN DB
Mizuki, Nobuhisa Browse this author →KAKEN DB
Kamoi, Koju Browse this author →KAKEN DB
Brezin, Antoine P. Browse this author
Dick, Andrew D. Browse this author
Jaffe, Glenn J. Browse this author
Nguyen, Quan Dong Browse this author
Inomata, Noritaka Browse this author
Kwatra, Nisha V. Browse this author
Camez, Anne Browse this author
Song, Alexandra P. Browse this author
Kron, Martina Browse this author
Tari, Samir Browse this author
Ohno, Shigeaki Browse this author →KAKEN DB
Keywords: Active uveitis
inactive uveitis
non-infectious uveitis
ocular inflammation
Issue Date: 2-Jan-2019
Publisher: Taylor & Francis
Journal Title: Ocular immunology and inflammation
Volume: 27
Issue: 1
Start Page: 40
End Page: 50
Publisher DOI: 10.1080/09273948.2018.1491605
PMID: 30015528
Abstract: Purpose: Report global adalimumab safety and efficacy outcomes in patients with non-infectious uveitis. Methods: Adults with non-infectious intermediate, posterior, or panuveitis were randomized 1:1 to receive placebo or adalimumab in the VISUAL I (active uveitis) or VISUAL II (inactive uveitis) trials. Integrated global and Japan substudy results are reported. The primary endpoint was time to treatment failure (TF). Results: In the integrated studies, TF risk was significantly reduced (hazard ratio [95% CI]) with adalimumab versus placebo (VISUAL I: HR = 0.56 [0.40-0.76], p < 0.001; VISUAL II: HR = 0.52 [0.37-0.74], p < 0.001). In Japan substudies, no consistent trends were observed between groups (VISUAL I: HR = 1.20 [0.41-3.54]; VISUAL II: HR = 0.45 [0.20-1.03]). Adverse event rates were similar between treatment groups in both studies (854 to 1063 events/100 participant-years). Conclusions: Adalimumab lowered time to TF versus placebo in the integrated population; no consistent trends were observed in Japan substudies. Safety results were consistent between studies.
Type: article
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 大野 重昭

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University